comprehensive -WSS

comprehensive

author：fashion 2025-09-30 00:35:22 - browse：15

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

As a primary care physician, here's how I hope to partner with AI

Making the case for fair compensation in clinical trials

Roche to buy Carmot Therapeutics, developer of obesity drugs

FDA approves world's first CRISPR

Chemotherapy shortages won’t get better under Biden’s latest plan

entertainment

comprehensive

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Pharma patents targeted by Biden in move to slash drug prices

Peter Hotez and the public health issue of online harassment

Study finds gene variants tied to breast cancer risk in Black women

23andMe had bad news about my health. I wish a person had delivered it

AI models in health care face new federal disclosure requirements

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

focus

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Pfizer plans to depart BIO

AI models in health care face new federal disclosure requirements

Teach medical students about patients with intellectual disabilities

Liver decline slowed by off

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

explore

knowledge

entertainment

leisure time